As people age, their immune systems age, too. And new research at Washington University School of Medicine in St. Louis suggests that aging immune cells increase the risk for age-related macular degeneration, a major cause of blindness in the United States.
Studying mice and cells from patients, the researchers found that as immune cells called macrophages age, they are more likely to contribute to the inflammation and abnormal blood vessel growth that damage vision in macular degeneration.
Their findings are published April 5 in the journal JCI Insight.
"Drug treatments for macular degeneration aren't effective for some patients, who either have a minimal response or not response at all, and many patients continue to experience vision loss over the long term, even if they have a good initial response to treatment," said senior investigator Rajendra S. Apte, MD, PhD, the Paul A. Cibis Distinguished Professor of Ophthalmology and Visual Sciences. "But by understanding what happens with the immune cells in the eye, it may be possible to develop therapies to help patients who can't be helped with existing drugs."
In experiments in mice, Apte's team found that older macrophages carry larger amounts of short snippets of genetic material, called microRNAs, that govern how cells express genes. The researchers found significantly higher levels of microRNA-150 in macrophages in the eyes of older mice.
MicroRNAs help regulate many things in cells by binding to several genes to influence how those genes make proteins. In this study, the researchers found that microRNA-150 seemed to be guiding older macrophages toward promoting inflammation and abnormal blood vessel formation in a mouse model of macular degeneration.
The researchers also tested blood samples from human subjects with and without macular degeneration. The samples from those with macular degeneration also had significantly higher levels of microRNA-150 in their macrophages.
"We think microRNA-150 may be a potential therapeutic target, or at least a biomarker, for aggressive disease and risk of vision loss," said first author Jonathan B. Lin, an MD/PhD student at the School of Medicine.
In the United States, almost 11 million people have some form of age-related macular degeneration, with the number expected to top 22 million by 2050. It affects women more than men, and the majority of patients are Caucasian. One early symptom is blurry vision in which straight lines appear distorted. That can progress to darkness, whiteouts or blurry areas in the center of the visual field. The disease does not, by itself, lead to total blindness because peripheral vision remains unaffected. Although some therapies delay loss of central vision, no current treatments restore it completely.
"Macular degeneration therapies seem to be treating disease symptoms, rather than its cause," Lin said. "We focused on the role of macrophages in regulating inflammation and the growth of abnormal blood vessels to see whether it may be possible one day to help people who don't get much benefit from existing treatments and design therapies that may prevent progression to advanced forms of the disease."
Lin and Apte said if they could somehow reduce microRNA levels in macrophages, or alter one or more molecular pathways regulated by this microRNA, they might be able to lower levels of inflammation and interfere with abnormal blood vessel growth in the eye. They also believe similar strategies eventually may help patients with other diseases related to aging.
"It's possible to envision immune-based therapies that would tweak the level of microRNAs so that these macrophage cells no longer contribute to disease," said Apte. "Such therapies are a long way off, and we need to do a lot more research, but if we could make these older cells more like the younger ones, we might be able to prevent a great deal of vision loss."
Lin JB, Moolani HV, Sene A, Sidhu R, Kell P, Lin JB, Dong Z, Ban N, Ory DS, Apte RS. Macrophage microRNA-150 promotes pathological angiogenesis as seen in age-related macular degeneration. JCI Insight, vol. 3 (7), April 5, 2018. https:/
This work was supported by the National Eye Institute, the National Institute of Diabetes and Digestive and Kidney Diseases, the National Cancer Institute and the National Institute of General Medical Sciences of the National Institutes of Health (NIH), grant numbers R01 EY019287, P30 EY02687, P30 DK020579, UL1 TR000448, P30 CA91842, T32 GM07200, UL1 TR002345, TL1 TR002344. Additional funding from the Starr Foundation, the Carl Marshall Reeves and Mildred Almen Reeves Foundation, the Bill and Emily Kuzma Family, Research to Prevent Blindness, the Jeffrey Fort Innovation Fund, the Glenn Foundation, the Thome Foundation and the VitreoRetinal Surgery Foundation.
Washington University School of Medicine's 1,300 faculty physicians also are the medical staff of Barnes-Jewish and St. Louis Children's hospitals. The School of Medicine is a leader in medical research, teaching and patient care, ranking among the top 10 medical schools in the nation by U.S. News & World Report. Through its affiliations with Barnes-Jewish and St. Louis Children's hospitals, the School of Medicine is linked to BJC HealthCare.